Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals' board, meeting on 12 November 2025, approved the unaudited standalone financial results for Q2 FY26 and H1 FY26 (ended 30 September 2025). Revenue from operations for Q2 was ₹1,762.11 lakhs, almost flat compared to ₹1,770.49 lakhs in Q2 FY25. H1 FY26 revenue came in at ₹3,432.01 lakhs, marginally lower than ₹3,475.43 lakhs in H1 FY25. Profit after tax for Q2 rose modestly to ₹52.43 lakhs (from ₹50.02 lakhs), while H1 PAT grew about 12% to ₹74.76 lakhs. The statutory auditor (Dileep & Prithvi) issued a clean, unmodified limited review report with no qualifications or emphasis of matter. The company continues to operate in a single segment – Ayurvedic medicines.
A nearly flat top line but improving profitability and strong operating cash flow of ₹241.84 lakhs suggest stable business performance. Shareholders should view this as a routine quarterly update with no negative flags, though revenue growth remains soft.